Navigation Links
NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
Date:4/2/2013

AMES, Iowa, April 2, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer. The Phase 2 clinical study will evaluate indoximod as a new approach to treating cancer by administering this novel IDO pathway inhibitor, designed to counteract a key mechanism by which tumors evade immune-mediated destruction, in combination with a conventional cytotoxin, docetaxel. This Phase 2 clinical study follows the successful Phase 1b dose-escalation study of indoximod in patients with advanced solid tumors in which a favorable safety profile and promising early signs of activity were observed. Indoximod is the most advanced product candidate to enter clinical trials based on NewLink's proprietary IDO pathway inhibitor platform for small-molecule, orally bioavailable cancer immunotherapies.

"There is significant unmet need for new approaches that may offer more effective treatment options for patients with metastatic breast cancer, a leading cause of death in women in the United States," said Hatem Soliman , MD, a medical oncologist specializing in breast cancer in The Center for Women's Oncology at Moffitt Cancer Center and the principal investigator for this study. "Indoximod has demonstrated promising safety, pharmacokinetic and biologic activity in earlier clinical studies and we look forward to increasing our understanding of its potential in metastatic breast cancer with this robust Phase 2 study designed to evaluate the activity of indoximod in combination with a co
'/>"/>

SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Epigenetics: Changing the Way We Think about DNA
2. Research and Markets: Cytogenetics - Technologies, Markets and Companies - 2013
3. Plunketts Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
4. Plunketts Biotech & Genetics Industry Trends & Statistics 2013: A Summary Version of Plunketts Biotech & Genetics Industry Almanac 2013
5. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
6. The American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee Recommend Noninvasive Prenatal Testing for Fetal Aneuploidy
7. Response Genetics, Inc. to Offer ROS1 Testing for Lung Cancer
8. Epigenetics Holds Key to Healthier Future
9. Response Genetics, Inc. Announces Second Quarter Financial Results
10. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
11. Applied Genetics Initiates Commercial Operation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/20/2014)... 20, 2014 Local veterinary surgeon, Dr. ... investigational study of donor stem cells for dogs with ... therapy and has performed clinical stem cell therapy for ... to determine if a single injection of donor stem ... help reduce pain and inflammation in the treated joints. ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... bromine market in Asia-Pacific with analysis and forecast ... the Asia Pacific Bromine Market report, to get ... also provides a glimpse of the segmentation in ... various tables and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... Families Can Invest Simultaneously in Future Healthcare and ... Inc., one of the world,s largest and most ... stem cell innovation, recently,renewed their agreement as an ... college funding contributions in America. Since,2004, Cryo-Cell has ...
... Sheets: CGCP), a leading developer of surgical products,used in ... financial results for its third quarter ended September 30, ... the third quarter of 2008 totaled $2,618,000, a 25% ... The lower revenue in,the current year quarter is primarily ...
... (Nasdaq: MEMY ), today reported its financial ... "Our results reflect continued clinical progress on ... into innovative therapies,",stated Vaughn M. Kailian, President and ... agreement with Roche to enhance our,ongoing Phase 2 ...
Cached Biology Technology:Cryo-Cell Renews Upromise Industry-Exclusive Agreement 2Cryo-Cell Renews Upromise Industry-Exclusive Agreement 3Cryo-Cell Renews Upromise Industry-Exclusive Agreement 4Cardiogenesis Reports Third Quarter 2008 Results 2Cardiogenesis Reports Third Quarter 2008 Results 3Cardiogenesis Reports Third Quarter 2008 Results 4Cardiogenesis Reports Third Quarter 2008 Results 5Cardiogenesis Reports Third Quarter 2008 Results 6Cardiogenesis Reports Third Quarter 2008 Results 7Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 2Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 3Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 4Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 5Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 6Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 7Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results 8
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
(Date:10/14/2014)... led by researchers at the University of Massachusetts ... Miller School of Medicine (UMMSM) have identified what ... (manic depressive) disorder, a breakthrough that could lead ... as well as depression and other related mood ... week in Nature Molecular Psychiatry , show ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... fracture) in women is highly recognized by the public. Less appreciated ... two million males have been diagnosed with osteoporosis and another three ... are thought to be major factors behind bone fractures in both ... low levels of the testosterone are known to be at risk. ...
... HARBOR, N.Y. In 1911, the influential geneticist Charles ... his ideas of how genetics would improve society in the ... foundation for the widespread eugenics movement in the United States. ... the 20th century have long been rejected, many of the ...
... University of Minnesota School of Public Health researchers have ... are less likely to engage in healthy activities such ... meals. They also consumed larger quantities of sweetened beverages ... and read or studied less than teens without TVs ...
Cached Biology News:Testosterone replacement theraphy beneficial in men 60 and older 2Testosterone replacement theraphy beneficial in men 60 and older 3Reflecting on the social implications of human genetics research -- past, present and future 2U of M research finds teens who have TV in their bedroom are less likely to engage in healthy habits 2
Please email us with project details and we will respond within 24 hours to your query!...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
Request Info...
Request Info...
Biology Products: